Department of Radiology.
Department of Nuclear Medicine, Lanzhou University Second Hospital.
Nucl Med Commun. 2022 Mar 1;43(3):310-322. doi: 10.1097/MNM.0000000000001519.
To develop nomograms that combine clinical characteristics, computed tomographic (CT) features and 18F-fluorodeoxyglucose PET (18F-FDG PET) metabolic parameters for individual prediction of epidermal growth factor receptor (EGFR) mutation status and exon 19 deletion mutation and exon 21 point mutation (21 L858R) subtypes in lung adenocarcinoma.
In total 124 lung adenocarcinoma patients who underwent EGFR mutation testing and whole-body 18F-FDG PET/CT were enrolled. Each patient's clinical characteristics (age, sex, smoking history, etc.), CT features (size, location, margins, etc.) and four metabolic parameters (SUVmax, SUVmean, MTV and TLG) were recorded and analyzed. Logistic regression analyses were performed to screen for significant predictors of EGFR mutation status and subtypes, and these predictors were presented as easy-to-use nomograms.
According to the results of multiple regression analysis, three nomograms for individualized prediction of EGFR mutation status and subtypes were constructed. The area under curve values of three nomograms were 0.852 (95% CI, 0.783-0.920), 0.857 (95% CI, 0.778-0.937) and 0.893 (95% CI, 0.819-0.968) of EGFR mutation vs. wild-type, 19 deletion mutation vs. wild-type and 21 L858R vs. wild-type, respectively. Only calcification showed significant differences between the EGFR 19 deletion and 21 L858R mutations.
EGFR 21 L858R mutation was more likely to be nonsolid texture with air bronchograms and pleural retraction on CT images. And they were more likely to be associated with lower FDG metabolic activity compared with those wild-types. The sex difference was mainly caused by the 19 deletion mutation, and calcification was more frequent in them.
建立联合临床特征、计算机断层扫描(CT)特征和 18F-氟代脱氧葡萄糖 PET(18F-FDG PET)代谢参数的列线图,用于个体预测肺腺癌中表皮生长因子受体(EGFR)突变状态以及外显子 19 缺失突变和外显子 21 点突变(21 L858R)亚型。
共纳入 124 例接受 EGFR 突变检测和全身 18F-FDG PET/CT 的肺腺癌患者。记录并分析每位患者的临床特征(年龄、性别、吸烟史等)、CT 特征(大小、位置、边缘等)和四个代谢参数(SUVmax、SUVmean、MTV 和 TLG)。采用 logistic 回归分析筛选 EGFR 突变状态和亚型的显著预测因子,并将这些预测因子表示为易于使用的列线图。
根据多元回归分析结果,构建了 3 个用于个体化预测 EGFR 突变状态和亚型的列线图。三个列线图预测 EGFR 突变状态的曲线下面积值分别为 0.852(95%CI,0.783-0.920)、0.857(95%CI,0.778-0.937)和 0.893(95%CI,0.819-0.968);预测 EGFR 外显子 19 缺失突变与野生型、21 L858R 突变与野生型的曲线下面积值分别为 0.857(95%CI,0.778-0.937)和 0.893(95%CI,0.819-0.968)。只有钙化在外显子 19 缺失和 21 L858R 突变之间显示出显著差异。
CT 图像上,EGFR 21 L858R 突变更可能为非实性成分,伴有空气支气管征和胸膜回缩。与野生型相比,它们更可能与较低的 FDG 代谢活性相关。性别差异主要是由外显子 19 缺失突变引起的,并且它们更常发生钙化。